Sotagliflozin with insulin for treating type 1 diabetes – guidance (TA622)

NICE recommends sotagliflozin with insulin as an option for treating type 1 diabetes in adults with a BMI of at least 27 kg/m2, when insulin alone does not provide adequate glycaemic control despite optimal insulin therapy, only if certain criteria are met.

SPS commentary:

The set criteria are:

    Sotagliflozin is given as one 200 mg tablet dailyThe patient is on insulin doses of 0.5 units/kg of body weight/day or more andThey have completed a structured education programme that is evidence based, quality assured, delivered by trained educators and includes information about diabetic ketoacidosis, such as:
      how to recognise its risk factors, signs and symptomshow and when to monitor blood ketone levelswhat actions to take for elevated blood ketones and
    Treatment is to be started and supervised by a consultant physician specialising in endocrinology and diabetes treatment, and haemoglobin A1c (HbA1c) levels are assessed after 6 months and regularly after this.Sotagliflozin should be stopped if there has not been a sustained improvement in glycaemic control (that is, a fall in HbA1c level of about 0.3% or 3 mmol/mol).



National Institute for Health and Care Excellence